Navigation Links
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
Date:3/13/2008

ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that the Company is taking new initiatives to pursue the drug development program for its investigational product candidate, eprodisate (KIACTA(TM)), to obtain market approval for the treatment of Amyloid A (AA) amyloidosis. Neurochem's decision to build upon its eprodisate (KIACTA(TM)) asset and take steps to initiate a second Phase III clinical trial is based principally on the fact that AA amyloidosis is a life-threatening disease for which there is no specific treatment, on the data obtained from the first Phase II/III clinical trial, which yielded promising efficacy results on the study endpoints, on the benign safety profile of eprodisate (KIACTA(TM)) in patients diagnosed with AA amyloidosis, and on its discussions with the regulatory agencies and related scientific advisory committees. As part of the approval process for the investigational product candidate, both the regulatory agencies in the United States and in the European Union recommended an additional confirmatory efficacy Phase III clinical trial, which will have a target significance level (p-value) of 0.05 rather than the p-value of 0.01, which had been required for an approval based on a single efficacy study. Based on these recommendations, the Company will enter into discussions with the U.S. Food and Drug Administration (FDA) and with the European Medicines Agency (EMEA) to reach agreement on the terms for an approval of eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis. As part of this strategic decision, the Company is also announcing that it is withdrawing its current mark
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurochem reports results for third quarter of fiscal 2007
2. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
3. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem to present at JPMorgan Healthcare Conference
6. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
7. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
8. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
9. Neurochem announces departure of two members of management team
10. DSS Research Moves Corporate Office
11. Sutter Moves to Reduce Public Accountability, Slash Hospital Beds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer ... and more, is currently hosting a sweepstakes on its ... is open to U.S. residents age 18 and over, ... One lucky winner will then be selected at random ... card to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba ...
(Date:10/30/2014)... 2014 Graphics, coding, typography and search ... the craft of web design and require thorough knowledge ... simpler solution to create a website can be as ... information, customer reviews and Facebook posts all accumulate on ... the next evolution of how a business can develop ...
(Date:10/30/2014)... Calif. (PRWEB) October 30, 2014 ... mutually exclusive concepts in the medical-grade skin care ... the development of uniquely potent topical dermatological products, ... System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant ... glycolic acid concentrations (50% and 70%) and a ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer ... shoppers with a supply of sugardown®, a chewable dietary ... blood sugar spikes. Learning how to control blood sugar ... of a diabetes prevention plan. , Shoppers who spend ... tube of sugardown. The offer expires November 30. ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2
... , , , NEW YORK, June 10 Vendome ... magazines and producers of the HEALTHCARE DESIGN.09 Conference announces the 2009 ... those who are unable to afford the cost of the conference ... fee. , , "We believe, as a company ...
... condition in which patients, aortic valves have just two leaflets instead ... up to two percent of the general population. The defect ... the valve and may results in a feeling of tightness in ... is easily diagnosed; often physicians can hear a "click" or a ...
... vomiting disease invades cells by attaching to particular sugar ... the conclusion of a thesis presented at the Sahlgrenska ... an important step in the development of a drug ... Winter vomiting disease is an infectious inflammation ...
... Illinois, USA June 10, 2009 The most important ... are the types of diagnostic tests performed and whether or ... they can ensure that only patients who need readily accessible ... study published today in the Journal of Hospital Medicine ...
... search platform to enable healthcare professionals to find Medicare ... 10 Vivisimo ( www.vivisimo.com ), a ... provider of education and information on healthcare regulatory compliance ... platform to power search on ...
... Organizations team pilot chronic care management tools in a ... Microsoft Corp., in collaboration with the University ... Family Medicine and Community Health, the city of Miami, ... in Miami,s Overtown neighborhood aimed at changing the way ...
Cached Medicine News:Health News:HEALTHCARE DESIGN.09 Announces Scholarship Program 2Health News:First-degree relatives of patients with bicuspid aortic valve should be screened 2Health News:Drugs against winter vomiting disease one step closer 2Health News:Availability of diagnostic tests drive success in hospitalist-run short-stay units 2Health News:HCPro Selects Vivisimo Velocity to Launch MedicareFind.com 2Health News:HCPro Selects Vivisimo Velocity to Launch MedicareFind.com 3Health News:The University of Miami Miller School of Medicine, the City of Miami, Microsoft and Resolute Solutions Seek to Improve Care of Diabetic Populations Using Collaborative Technology 2Health News:The University of Miami Miller School of Medicine, the City of Miami, Microsoft and Resolute Solutions Seek to Improve Care of Diabetic Populations Using Collaborative Technology 3
(Date:10/30/2014)... FARMINGDALE, N.Y. , Oct. 30, 2014  Misonix, ... surgical device company that designs, manufactures and markets innovative ... surgical specialties, announced today that it will report financial ... Thursday, November 6, 2014. The Company has scheduled a ... at 4:30 pm ET to review the results. ...
(Date:10/30/2014)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology, and medical device industries, ... the United States , today announced ... Tel Aviv area of Israel.  ... platform of integrated R&D services to local customers. It ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4
... Inc.,("CeloNova"), leading and accelerating healthcare solutions through ... breakthrough,results from the ATLANTA study of the ... the 20th Annual International Symposium on,Endovascular Therapy ... Corrado Tamburino, MD, President of the ...
... Ortho Women,s Health,& Urology(TM), Division of ... for ORTHO EVRA(R),(norelgestromin/ethinyl estradiol transdermal system) to ... includes two new additional estimates of relative,risk ... of 1.1,(indicating no increase in risk) and ...
Cached Medicine Technology:CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F 2ORTHO EVRA(R) Prescribing Information Updated 2ORTHO EVRA(R) Prescribing Information Updated 3
... IOL is a foldable silicone IOL. It ... and is designed to be inserted with ... Multifocal IOL is the first and only ... offer patients a full range of functional ...
1% Sodium Hyaluronate, 10mg/mL, sterile opthalmic injection...
... Ocucoat is a 2% Hydroxypropyl Methylcellulose solution ... surgeons performing high volume, small incision surgery. ... allows for rapid removal with minimal risk ... Ocucoat permits an unobstructed view of the ...
... Amvisc is the right viscoelastic agent for ... the planned extracap technique. Amvisc possesses sufficient ... removal. Amvisc is highly cohesive so that ... case is easily and quickly accomplished. Amvisc ...
Medicine Products: